ATRx Labs

cbdMD Reports YoY Dip In Q1 Net Sales, Shrinks Operating Loss, Expands Into Hemp And Mushroom Products Markets
Medical cannabis company cbdMD has reported financial results for its first quarter of fiscal 2024. Operating loss improved to $1.1m compared to $4.1m for the same period in the previous year. Gross profit was flat at around $3.5m, while operating expenses were $4.6m, down from $7.6m in the previous year. Total net sales declined to $5.37m from almost $6m in the corresponding prior-year period. Direct-to-consumer net sales represented 82.3% of total net sales, a decrease from 90% in Q1 2023. On 31 December 2023, cbdMD had total working capital of roughly $1.4m compared to approximately $3.4m on 30 September, with cash on hand dropping to roughly $1.5m from $1.8m over the same period. The Charlotte-based company recently struck a securities purchase agreement with five institutional investors to fund the national rollout of its ATRx Labs functional mushroom products, as well as launching the hempMD and ATRx Labs brands.
Medical Cannabis Pioneer cbdMD Secures $1.2M To Fund Rollout Of Functional Mushroom Products
Medical cannabis producer cbdMD has secured $1.25m in financing from five institutional investors to support the national rollout of its new ATRx Labs functional mushroom products. North Carolina-based cbdMD will use the proceeds for working capital as well. The news comes after the company launched two new products--Apple Cider Vinegar (ACV) and Immunity Gummy Pouches-through grocery chain Sprouts Farmers Market. Sprouts chose cbdMD to be a leading brand in its CBD section. The institutional investors will receive a senior secured original issue discount convertible promissory note, which matures 18 months from the date of issue. At that point, the notes can be converted into shares at a rate of $0.684 per share.